Anti-NAP1L2 monoclonal antibody

Pre-made anti-NAP1L2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to NAP1L2/NAP1L2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2622-Ab-1/ GM-Tg-hg-IP2622-Ab-2Anti-Human NAP1L2 monoclonal antibodyHuman
GM-Tg-rg-IP2622-Ab-1/ GM-Tg-rg-IP2622-Ab-2Anti-Rat NAP1L2 monoclonal antibodyRat
GM-Tg-mg-IP2622-Ab-1/ GM-Tg-mg-IP2622-Ab-2Anti-Mouse NAP1L2 monoclonal antibodyMouse
GM-Tg-cynog-IP2622-Ab-1/ GM-Tg-cynog-IP2622-Ab-2Anti-Cynomolgus/ Rhesus macaque NAP1L2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2622-Ab-1/ GM-Tg-felg-IP2622-Ab-2Anti-Feline NAP1L2 monoclonal antibodyFeline
GM-Tg-cang-IP2622-Ab-1/ GM-Tg-cang-IP2622-Ab-2Anti-Canine NAP1L2 monoclonal antibodyCanine
GM-Tg-bovg-IP2622-Ab-1/ GM-Tg-bovg-IP2622-Ab-2Anti-Bovine NAP1L2 monoclonal antibodyBovine
GM-Tg-equg-IP2622-Ab-1/ GM-Tg-equg-IP2622-Ab-2Anti-Equine NAP1L2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2622-Ab-1/ GM-Tg-hg-IP2622-Ab-2; GM-Tg-rg-IP2622-Ab-1/ GM-Tg-rg-IP2622-Ab-2;
GM-Tg-mg-IP2622-Ab-1/ GM-Tg-mg-IP2622-Ab-2; GM-Tg-cynog-IP2622-Ab-1/ GM-Tg-cynog-IP2622-Ab-2;
GM-Tg-felg-IP2622-Ab-1/ GM-Tg-felg-IP2622-Ab-2; GM-Tg-cang-IP2622-Ab-1/ GM-Tg-cang-IP2622-Ab-2;
GM-Tg-bovg-IP2622-Ab-1/ GM-Tg-bovg-IP2622-Ab-2; GM-Tg-equg-IP2622-Ab-1/ GM-Tg-equg-IP2622-Ab-2
Products NameAnti-NAP1L2 monoclonal antibody
Formatmab
Target NameNAP1L2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-NAP1L2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2622-Ag-1Recombinant multi-species NP1L2/ NAP1L2/ BPX protein


    Target information

    Target IDGM-IP2622
    Target NameNAP1L2
    Gene ID4674,17954,317247,701017,491959,101097625,100059481
    Gene Symbol and SynonymsBPX,NAP1L2
    Uniprot AccessionQ9ULW6
    Uniprot Entry NameNP1L2_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000186462
    Target ClassificationN/A

    The target: NAP1L2, gene name: NAP1L2, also named as BPX. The protein encoded by this intronless gene is a member of the nucleosome assembly protein (NAP) family. The encoded protein represents a class of tissue-specific factors that interact with chromatin to regulate neuronal cell proliferation. [provided by RefSeq, Jan 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.